A pan-European survey of antimicrobial susceptibility towards human-use antimicrobial drugs among zoonotic and commensal enteric bacteria isolated from healthy food-producing animals
Authors:
Open Access
- 17 February 2009
- journal article
- research article
- Published by Oxford University Press (OUP) in Journal of Antimicrobial Chemotherapy
- Vol. 63 (4) , 733-744
Abstract
The aim of the study was to study antimicrobial susceptibility in Escherichia coli, Salmonella, Campylobacter and Enterococcus recovered from chickens, pigs and cattle using uniform methodology. Intestinal samples were taken at slaughter in five EU countries per host and bacteria isolated in national laboratories. MICs were determined in a central laboratory of key antimicrobials used in human medicine. Clinical resistance was based on CLSI breakpoints and decreased susceptibility on EFSA epidemiological cut-off values. Isolation rates from a total of 1500 samples were high for E. coli (n=1465), low for Salmonella (n=205) and intermediate for Campylobacter (n=785) and Enterococcus (n=718). Resistance prevalence varied among antibiotics, bacteria, hosts and countries. For E. coli and Salmonella, clinical resistance to newer compounds (cefepime, cefotaxime, ciprofloxacin) was absent or low, but a decreased susceptibility was apparent, particularly in chickens. Clinical resistance to older compounds (except colistin and gentamicin) was variable and higher. For Campylobacter jejuni from chickens, ciprofloxacin resistance was markedly higher than in isolates from cattle. Clinical resistance to erythromycin was absent for both hosts; decreased susceptibility very low. Similar trends were determined for Campylobacter coli, but C. jejuni was less resistant. None of the enterococcal strains was resistant to linezolid, but a few displayed resistance to ampicillin or vancomycin. Resistance prevalence to quinupristin/dalfopristin was clearly higher. Antimicrobial resistance among enteric organisms in food animals varied among countries, particularly for older antimicrobials, but clinical resistance to essential compounds used to treat disease in humans was generally zero or low. In the absence of clinical resistance to newer compounds in E. coli and Salmonella, the apparent decreased susceptibility should be monitored carefully.Keywords
This publication has 18 references indexed in Scilit:
- Emergence of CC17Enterococcus faecium: from commensal to hospital-adapted pathogenFEMS Immunology & Medical Microbiology, 2008
- Has Retail Chicken Played a Role in the Decline of Human Campylobacteriosis?Applied and Environmental Microbiology, 2008
- Potential confusion regarding the term 'resistance' in epidemiological surveysJournal of Antimicrobial Chemotherapy, 2007
- Impact of the slaughter line contamination on the presence of Salmonella on broiler carcassesJournal of Applied Microbiology, 2006
- Antimicrobial breakpoints—Definitions and conflicting requirementsVeterinary Microbiology, 2006
- The susceptibility to growth-promoting antibiotics of Enterococcus faecium isolates from pigs and chickens in EuropeJournal of Antimicrobial Chemotherapy, 2005
- Quinolone Resistance Is Associated with Increased Risk of Invasive Illness or Death during Infection withSalmonellaSerotype TyphimuriumThe Journal of Infectious Diseases, 2004
- Reevaluating Fluoroquinolone Breakpoints for Salmonella enterica Serotype Typhi and for Non-Typhi SalmonellaeClinical Infectious Diseases, 2003
- Reduced Fluoroquinolone Susceptibility in Salmonella enterica Serotypes in Travelers Returning from Southeast AsiaEmerging Infectious Diseases, 2001
- Drug-Resistant Salmonella from Animals Fed AntimicrobialsNew England Journal of Medicine, 1984